11:31:31 EDT Mon 15 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Sona Nanotech Inc
Symbol SONA
Shares Issued 95,095,360
Close 2023-09-11 C$ 0.19
Market Cap C$ 18,068,118
Recent Sedar Documents

Sona, Giacomantonio to conduct THT efficacy study

2023-09-11 14:33 ET - News Release

Mr. David Regan reports

SONA'S 'THT' CANCER THERAPY TO BE ASSESSED FOR EFFICACY AND ABILITY TO ACT AS A CATALYST TO GENERATE IMMUNE RESPONSES IN RESEARCH STUDY

Sona Nanotech Inc. is undertaking an innovative research initiative with the Giacomantonio Immuno-Oncology Research Group (the research group). This study aims to evaluate the efficacy of Sona's Targeted Hyperthermia therapy (THT) technology in not only attenuating the development of colorectal, breast and melanoma tumour models in mice but also in facilitating systemic immune responses.

The study posits that the combined utilization of Sona's gold nanorods via its Targeted Hyperthermia therapy, alongside precise immune modulation, will result in elevated immune activation and anti-tumour responses within the mouse models of colorectal cancer, breast cancer and melanoma.

Sona chief executive officer David Regan commented: "This innovative study will go significantly beyond our current plans for Targeted Hyperthermia therapy applications to explore the potentially synergistic effect of its use with certain immunotherapy treatments for cancer. In it, we aim to harness the tremendous potential of immunotherapy, leveraging Sona's biocompatible gold nanorods as a pivotal, catalytic element. This effort marks the beginning of Sona delivering on the 'mountain of data' we committed to developing in support of our planned regulatory submissions for human clinical trial approvals."

Dr. Carman Giacomantonio, principal investigator of the research group, commented: "We are committed to exploring two distinct yet interrelated biological processes with the potential to unlock the elusive holy grail of intratumoural cancer immunotherapies, known as the abscopal effect. The first avenue capitalizes on the kinetic excitation of gold nanorods, capable of inducing localized tumour destruction. This process exposes potent tumour neo-antigens, which can then be strategically mobilized to immune-responsive sites. This strategy holds the potential of profoundly reshaping and amplifying the efficacy of the immune response against cancer. Concurrently, the second dimension of our research delves into the profound impact of intralesional immunomodulation in the context of both local and systemic Targeted Hyperthermia therapy. Together, these objectives, if successful, may establish a strategic framework to illuminate the path towards groundbreaking, innovative and potent immunotherapeutic interventions for colorectal cancer, breast cancer and melanoma."

Sona chief scientifici officer Len Pagliaro, PhD, commented: "We are excited and pleased to have the opportunity to collaborate with the Giacomantonio Immuno-Oncology Research Group. The planned studies will bring the extensive knowledge and experience of Dr. Giacomantonio to bear in an elegant and sophisticated study that will increase our understanding of both the mechanisms and capabilities of THT. The findings of this study will help inform and improve our planned first-in-human studies as we approach that important milestone."

To facilitate the study, the company and the research group have entered into a research agreement under which experiments will be conducted. The experiments will explore immune reprogramming by tumour antigen transfer, as well as tumour response and immune modulation, in subcutaneous tumour models following treatment with various immunotherapeutic interventions. The company will cover up to a maximum of $80,000, which is approximately 40 per cent of the study's anticipated cost, which will include in-kind contributions of the company and its laboratory. The research group will provide various interim results to be provided to the company and will have the right to publish findings from the study. The study is to be conducted at the Giacomantonio Laboratory at Dalhousie University in Halifax, N.S. The results of the study are anticipated to provide data that will form part of any future regulatory submissions in support of the development of the company's Targeted Hyperthermia therapy.

About Sona Nanotech Inc.

Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumours. The heat is delivered to tumours by infrared light that is absorbed by Sona's gold nanorods in the tumuor and re-emitted as heat. Therapeutic heat (44 C) stimulates the immune system, shrinks tumours, inactivates cancer stem cells and increases tumour perfusion, thus enabling drugs to reach all tumour compartments more effectively. The size, shape and surface chemistry of the nanorods target the leaky vasculature of solid tumours and the selective thermal sensitivity of tumour tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive and competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Sona's initial clinical target is colorectal cancer.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium (CTAB) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the U.S. Food and Drug Administration.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.